Clinical Trial Update: Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating efficacy, safety, and immunogenicity of GSK's herpes zoster vaccine in adults 50+ completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• GSK1437173A (GSK1437173A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-05-01